About severe hypoglycemi

Any serious hypoglycemic event is a daily concern of diabetic patients. Mild or moderate hypoglycemia can occur many times a month. Severe hypoglycemia is characterized by severe cognitive impairment, requiring external assistance for recovery, and can be terrible for patients and nurses. Severe hypoglycemia can lead to cardiovascular disease, seizures, coma, and death if not treated in time. These severe hypoglycemic events can occur many times a year. Such incidents require emergency assistance from other people or caregivers, such as family members, friends or colleagues.

About Glucagon

Glucagon is a metabolic hormone secreted by the pancreas, which raises blood sugar levels by rapidly converting glycogen (stored in the form of glucose) into glucose by the liver, which is then released into the blood. Glucagon and insulin are two key hormones in the blood sugar control system, which keep blood sugar at an appropriate level in healthy individuals. In insulin-dependent diabetic patients, the control system is destroyed and insulin must be injected to avoid high levels of blood sugar (hyperglycemia). The opposite effect or hypoglycemia (hypoglycemia) is also common in this population due to the disorder of glucagon secretion. Severe hypoglycemia is a serious disease that can lead to seizures, coma, potential brain damage, and death if untreated.

Glucagon is the standard treatment for severe hypoglycemia. According to the regulations of the American Diabetes Association, glucagon should be prescribed for all patients with clinically significant increased risk of hypoglycemia, defined as blood sugar < 54 mg/dL (3.0 mmol/L). Using XeriSol, the two proprietary formulation platforms of Xeri, Xeris may provide the first ready-to-use, room-temperature stable liquid glucagon for use by diabetics and other patients with diseases to prevent or manage various forms of hypoglycemia and improve glycemic control.

About Xeris Pharmaceuticals, Inc.

Xeris is a professional pharmaceutical company, using its innovative technology platform to develop commercial ready-to-use, room temperature stable injection and insoluble drug formulations. The company's proprietary XeriSol and XeriJect formulation technology is evaluating the use of commercially available injectors, automatic syringes, multi-dose pens and infusion pumps for subcutaneous (SC) and intramuscular (IM) delivery of high-concentration, non-aqueous, ready-to-use peptide, small molecule, protein and antibody formulations. XeriSol () and XeriJect () have obvious advantages over existing product formulations at the stage of marketing and development, including no reconfiguration, long-term, room temperature stability, significant reduction of injection volume, and elimination of intravenous (IV) infusion requirements. These attributes may lead to products that are easier for patients, nurses and medical practitioners to use, and lower costs for payers and health care systems.